Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables PQRI Leachables & Extractables Working Group PQRI Training Course.

Slides:

Advertisements

Similar presentations

Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.

Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.

Policy Advisory Group (PAG) & Technical Advisory Committee (TAC) Leader Primer Presented by: Devin A. Jopp, Ed.D. President & CEO.

Pira International Conference Extractables Testing for Pumps and Valves Francois Billard, M.S. Laboratory Manager, Valois of America October 2006.

Parametric Tolerance Interval (PTI) Test for Delivered Dose Uniformity (DDU) for Orally Inhaled and Nasal Drug Products (OINDP) Michael Golden On behalf.

Industry's Role in Promoting Best Practices A Collaborative Approach to Food Safety Global Food Safety Policy Forum Washington DC September 16, 2011.

Conference for FOOD PROTECTION Promoting Food Safety Through Collaboration.

1 PQRI Update For Drug and Pharmaceutical Packaging Committee Meeting June 13, 2011.

Pharmaceutical Product Quality Assurance Through CMC Drug Development Process Presented by Darlene Rosario (Aradigm) 21 October 2003 Meeting of the Advisory.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

ICH-GCG June 2009 Pan American Health Organization CURRENT STATUS OF PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION (PANDRH): James Fitzgerald.

Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.

FDA Nasal BA/BE Guidance Overview

September 2006PQRI Training Course1 Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables VIII. Quality Control and.

Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables PQRI Leachables & Extractables Working Group VI. Characterization.

Use and Care of Vertebrate Animals: What Researchers Need to Know Brian Greene IACUC Chair and Associate Professor of Biology Missouri State University.

ITFG/IPAC Collaboration OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD.

1 Process to Address Specifications for Delivered Dose Uniformity of Inhaled and Nasal Drug Products Presented by Robert O’Neill, Ph.D. Chair ACPS Working.

1 Lawrence Berkeley National Laboratory Integrated Safety Management Systems Review August 8-9, 2006 B erkeley Lab Safety Committee Presentation Paul Blodgett.

Pharmacologist & Toxicologist CTE Introduction. What is a Pharmacologist? Develop new drugs to cure, treat, and prevent disease. Develop new drugs to.

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary.

IPAC-RS GMP Guideline for OINDP Component Suppliers: Development, Application, and Use Barbara Falco (KOS), Chair of IPAC-RS Supplier Quality Control Working.

INTRODUCTION TO RA.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.

Forging Partnerships on Emerging Contaminants November 2, 2005 John Vandenberg Associate Director for Health National Center for Environmental Assessment.

+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.

Parametric Tolerance Interval Test for Delivered Dose Uniformity (DDU) Working Group Update Moheb M. Nasr, Ph.D. Office of New Quality Assessment (ONDQA,

Office of Pharmaceutical Sciences

Bioequivalence Studies and Other Recommendations for Orally Inhaled and Nasal Drug Products: Work of the ITFG/IPAC-RS Collaboration Presented by Cynthia.

About OMICS Group OMICS Group is an amalgamation of Open Access Publications and worldwide international science conferences and events. Established in.

1 ORALLY INHALED AND NASAL DRUG PRODUCTS FOR LOCAL ACTION Current FDA BA/BE Background and Issues Wallace P. Adams, Ph.D. OPS/CDER/FDA OINDP Subcommittee.

NIST: Promoting U.S. Innovation and Industrial Competitiveness Belinda L. Collins, Ph.D. Director, Technology Services.

Overview of FDA's Regulatory Framework for PET Drugs

TLV and BEI Committees: TLV ® and BEI ® Committees: The Decision Making Process Presented at AIHce May 13, 2003, Dallas, TX Bill Wells PhD, CIH, CSP, Moderator.

COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.

1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009.

UPDATE: Nonclinical Reproductive Toxicity Information in Assessing Human Risk Joseph J. DeGeorge Ph.D. Associate Director for Pharmacology and Toxicology.

1 Dose Content Uniformity for Aerosol Products Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 13 March 2003 Rockville, MD.

1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.

1 PTIT for DCU of OINDP: Approaches to Resolution of Identified Issues Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 21.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

ITFG/IPAC Collaboration Introduction OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD.

ANSI/Shared Assessments PHI Project – Organizational Structure Presented By: Jim McCabe Senior Director, Standards Facilitation American National Standards.

IPEC Overview The Impact of Globalisation and IPEC’s Role Janeen Skutnik Past Chair – IPEC Americas.

ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team ITFG/IPAC TECHNICAL TEAM: SUPPLIER QUALITY CONTROL (QUALIFICATION) Presented by: Gordon.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.

Orally Inhaled and Nasal Drug Products Subcommittee Introduction and Objectives Eric B. Sheinin Deputy Director Office of Pharmaceutical Science Center.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

Orally Inhaled and Nasal Drug Products (OINDP) Subcommittee Report to the Advisory Committee for Pharmaceutical Sciences Rockville, Maryland November 15,

December 1, 2004 Slide 1 Presented by Dan Bart, TIA and ANSI-HSSP Co-Chair December 1, 2004 Presentation on ANSI and the Homeland Security Standards Panel.

2010 James Fitzgerald Senior Advisor, Medicines and Health Technologies PAHO/WHO rd St Washington DC USA International Cooperation in Quality.

ITFG/IPAC Collaboration CMC Leachables and Extractables Technical Team ITFG/IPAC TECHNICAL TEAM: CMC LEACHABLES AND EXTRACTABLES Presented by: Kaushik.

Making Comments Count for High-Impact Regulations and Guidelines in the US Virginia (Ginny) Beakes-Read Executive Director, Global Regulatory Policy and.

Manufacturing Process of Drug Product: Container closure system Compatibility Ratiya KUKHETPITAKWONG 27 April 2016.

BSEE BAST Determination Process Joseph Levine National Ocean Industries Association 2016 Annual Meeting April 22, 2016 Washington, D.C “To promote safety,

Office of Pharmaceutical Science OPS Center for Drug Evaluation and Research CDER FDA Food and Drug Administration HHS Health and Human Services 1 Advisory.

Standards Coordination Office NIST presentation to the FGDC September 25, 2014.

GCP (GOOD CLINICAL PRACTISE)

Parametric Tolerance Interval (PTI) Test for Delivered Dose Uniformity (DDU) for Orally Inhaled and Nasal Drug Products (OINDP) Michael Golden On behalf.

Chapter 22 REGULATORY AND ADVISORY AGENCIES. Introduction 2.

Who Are We? A Forum of Stakeholders Who Come together to Develop Science-based Solutions.

How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.

FDA Tox Working Group Which goals of the FDA Roadmap are most important to FDA stakeholders? Integration of predictive technologies Replacing animal tests.

Beyond Science and Decisions: Problem Formulation to Dose Response

Pediatric Therapeutics Still working to get it right for kids

Quality guidelines on impurities

Presentation transcript:

Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables PQRI Leachables & Extractables Working Group PQRI Training Course September 20-21, 2006 Washington, DC

What are leachables and extractables? Extractables – Compounds that can be extracted from elastomeric, plastic components or coatings of the container and closure system when in the presence of an appropriate solvent(s). Extractables – Compounds that can be extracted from elastomeric, plastic components or coatings of the container and closure system when in the presence of an appropriate solvent(s). Leachables – Compounds that leach from elastomeric, plastic components or coatings of the container and closure system as a result of direct contact with the formulation. Leachables – Compounds that leach from elastomeric, plastic components or coatings of the container and closure system as a result of direct contact with the formulation.

What are OINDP? Metered Dose Inhalers Dry Powder Inhalers Inhalation Solutions Inhalation Sprays Nasal Sprays MDI Schematic Provided by Bespak Europe

Why are we interested leachables and extractables? FDA Guidances:FDA Guidances: Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products Chemistry, Manufacturing, and Controls Documentation;Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products Chemistry, Manufacturing, and Controls Documentation; Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Chemistry, Manufacturing, and Controls Documentation Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Chemistry, Manufacturing, and Controls Documentation Approvals:Approvals: We want them!!!!!!!We want them!!!!!!! Ethical and professional obligations.Ethical and professional obligations.

We want approvals!!!!!!!!!!!!!!

I’ve heard it all!!!!!!!!!! “A person is exposed to more PNAs standing behind a city bus than from an MDI.” “One charbroiled steak is equal to 1,000,000 MDIs!” “Bloody Americans – over the top as usual!!!!!!” “We have horror-stories.”

What is PQRI? Product Quality Research Institute Product Quality Research Institute Not-for-profit, non-stock, tax-exempt entity incorporated in Virginia Not-for-profit, non-stock, tax-exempt entity incorporated in Virginia Serves as a forum for academia, industry and FDA to work cooperatively Serves as a forum for academia, industry and FDA to work cooperatively Working Group on Leachables and Extractables currently in operation Working Group on Leachables and Extractables currently in operation

PQRI Member Organizations AAPS AAPS Consumer Healthcare Products Association Consumer Healthcare Products Association GPhA GPhA PDA PDA PhRMA PhRMA U.S. FDA, Center for Drug Evaluation and Research U.S. FDA, Center for Drug Evaluation and Research BIO BIO International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) International Pharmaceutical Excipients Council of the Americas (IPEC) International Pharmaceutical Excipients Council of the Americas (IPEC) USP USP

The International Pharmaceutical Aerosol Consortium (IPAC) formed in 1989 to address regulatory consequences for MDIs of Montreal and Kyoto ProtocolsThe International Pharmaceutical Aerosol Consortium (IPAC) formed in 1989 to address regulatory consequences for MDIs of Montreal and Kyoto Protocols In 2001, the International Pharmaceutical Aerosol Consortium for Regulation and Science (IPAC-RS) was officially formed as a separate ConsortiumIn 2001, the International Pharmaceutical Aerosol Consortium for Regulation and Science (IPAC-RS) was officially formed as a separate Consortium IPAC-RS Mission: To advance consensus- based and scientifically driven standards and regulations for inhaled and nasal drug products (OINDP).IPAC-RS Mission: To advance consensus- based and scientifically driven standards and regulations for inhaled and nasal drug products (OINDP). IPAC-RS Overall Goal: Development of scientifically justified regulatory approaches for orally inhaled and nasal drug productsIPAC-RS Overall Goal: Development of scientifically justified regulatory approaches for orally inhaled and nasal drug products

History of PQRI Leachables and Extractables Working Group Proposal to develop thresholds and examine best practices for L&E in OINDP drafted by IPAC-RS and submitted to PQRI Proposal to develop thresholds and examine best practices for L&E in OINDP drafted by IPAC-RS and submitted to PQRI Working Group formed in 2001, consisting of chemists and toxicologists from FDA, industry and academia Working Group formed in 2001, consisting of chemists and toxicologists from FDA, industry and academia Working Group developed a hypothesis and step-wise plan to investigate per established PQRI process Working Group developed a hypothesis and step-wise plan to investigate per established PQRI process Workplan approved by PQRI DPTC and Steering Committee in 2002 Workplan approved by PQRI DPTC and Steering Committee in 2002 Toxicologists and chemists formed sub-groups Toxicologists and chemists formed sub-groups

History of PQRI Leachables and Extractables Working Group Toxicologists: acquired data through extensive literature and database searches and analyses Toxicologists: acquired data through extensive literature and database searches and analyses Chemists: acquired data by conducting extractions studies and placebo leachables study Chemists: acquired data by conducting extractions studies and placebo leachables study Developed recommendations, “Safety Thresholds and Best Practices for Leachables and Extractables Testing in Orally Inhaled and Nasal Drug Products” Developed recommendations, “Safety Thresholds and Best Practices for Leachables and Extractables Testing in Orally Inhaled and Nasal Drug Products” Submitted final to PQRI and FDA in summer 2006 Submitted final to PQRI and FDA in summer 2006  Science and data-based recommendations to PQRI and FDA. Not a policy/regulatory document

Leachables and Extractables Working Group Members Dan Norwood, Chair (IPAC-RS) Doug Ball (IPAC-RS) Jim Blanchard (IPAC-RS) Lidiette Celado (AAPS) Fran DeGrazio (PDA) T.J. Deng (Lab - PPD) Bill Doub (Lab - FDA) Tom Feinberg (AAPS) Alan Hendricker (Lab - Cardinal) Jeff Hrkach (AAPS) Roger McClellan (UNM) Tim McGovern (FDA) Diane Paskiet (PDA) Paul Curry (USP) Michael Ruberto (Lab - CIBA) Alan Schroeder (FDA) Mark Vogel (PhRMA) Charles Wang (PhRMA) Ron Wolff (IPAC-RS) Michael Golden (DPTC, IPAC-RS) Guirag Poochikian (DPTC, FDA) Gordon Hansen (SC, IPAC-RS)

Recommendation Document Overview Introduction and Summary of Recommendations Introduction and Summary of Recommendations Derivation and justification of safety thresholds, and application of safety thresholds Derivation and justification of safety thresholds, and application of safety thresholds Chemistry Best Practices Chemistry Best Practices Appendices Appendices

Best Practices Overview Application of safety thresholds Application of safety thresholds  Safety Concern Threshold (SCT)  Qualification Threshold (QT) Integration of safety expertise into component selection, controlled extraction studies, leachables studies and routine extractables testing Integration of safety expertise into component selection, controlled extraction studies, leachables studies and routine extractables testing Analytical/chemistry Analytical/chemistry  Selection of components  Controlled Extraction Studies  Leachables Studies and Routine Extractables Testing  The Analytical Evaluation Threshold (AET)

Pharmaceutical Development Process for OINDP

Training Course Overview OINDP Container Closure Systems OINDP Container Closure Systems Safety Evaluation of Extractables and Leachables Safety Evaluation of Extractables and Leachables Analysis of Extractables and Leachables Analysis of Extractables and Leachables Characterization of Extractables Characterization of Extractables Characterization of Leachables Characterization of Leachables Special Case Compounds Special Case Compounds Quality Control and Specification Setting Quality Control and Specification Setting Team-based Activity Team-based Activity Panel Discussion Panel Discussion

Faculty Dan Norwood – Director Physical and Chemical Analysis, Boehringer Ingelheim Pharmaceuticals, Inc. (Working Group Chair) Diane Paskiet – Associate Director of Analytical Laboratories, West Monarch Analytical Labs Tom Feinberg – Senior Director, Pharmaceutical Development, Cardinal Health Doug Ball – Research Fellow, Drug Safety, Pfizer, Inc. (Toxicology Sub-group Chair) Terry Tougas – Highly Distinguished Scientist (BIPI) (DPTC Chair)

Feedback